E2 - BSA activates caveolin-1 via PI3K/ERK1/2 and lysosomal degradation pathway and contributes to EPC proliferation

BackgroundThe mechanism that estrogen (E2) increases the number of endothelial progenitor cells (EPC) is largely unknown. Here we used E2-conjugated bovine serum albumin (E2-BSA, membrane impermeable) to investigate whether the membrane estrogen receptor (mER) and its related protein caveolin-1 (CAV-1) are involved in these processes.Methods and resultsE2-BSA promoted [3H]-thymidine incorporation of EPC through increasing CAV-1 expression via mER (ERα, but not ERβ or GPR30). Both cholesterol depletion and CAV-1 knockdown with use of CAV-1 siRNA significantly attenuated E2-BSA-induced [3H]-thymidine incorporation. Western blot showed that E2-BSA increased membrane CAV-1 protein expression 12 h after treatment, whereas mRNA levels of CAV-1 were augmented until 24 h after E2-BSA treatment. Furthermore, pre-incubated EPC with ICI 182780 (a specific ER antagonist), LY 294002 (a selective PI3K inhibitor) or PD 98059 (a specific ERK1/2 inhibitor) before E2-BSA inhibited the late-stage effect of E2-BSA (≥ 24 h) on up-regulation of CAV-1 mRNA and protein expression. Pulse chase results demonstrated that E2-BSA inhibited lysosome-mediated degradation of CAV-1 protein at the early stage (≤ 12 h), and then resulted in the increased CAV-1 protein.ConclusionIn the present work we demonstrated that E2-BSA promotes EPC proliferation through mER（ERα）in CAV-1-dependent manner: prolonging the stability of CAV-1 protein through quick inhibition of the lysosomal degradation pathway at the early stage (≤ 12 h) and up-regulating CAV-1 at transcription levels through PI3K/ERK1/2 signaling pathway at the late stage (≥ 24 h). These data indicated that a there is a novel mechanism of E2-BSA in the regulation of EPC proliferation through CAV-1.